Abdul Wahid Ovaice Joins Huge as Global Executive Creative Director
Ovaice brings over 20 years of extensive creative experience to this role leading creative outputs for the global Google account...
News
Integrity Grows Medicare Presence in Pacific Northwest with Acquisition of D&D Insurance
DALLAS, Oct. 7, 2021 /PRNewswire/ -- Integrity Marketing Group, LLC ("Integrity"), one of the largest independent distributors of life, health...
Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A.
Dragon SPAC and Jaguar subsidiary Napo EU submit required notification to the Italian government in support of consummating the mergerResults...
Conference Call on Interim Report
GOTHENBURG, SE / ACCESSWIRE / October 7, 2021 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)Invitation to attend XVIVO's conference call...
Jupiter Wellness Provides Shareholder Update on Multiple Clinical & Commercial Milestones
JUPITER, FL / ACCESSWIRE / October 7, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today provided an update on its advancing...
Biotricity Launches Biocare Cardiac Application for Samsung’s Galaxy Watch4 Series
REDWOOD CITY, CA / ACCESSWIRE / October 7, 2021 / Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology...
Ground-Breaking Clinical Data from INSIGHT Trial Presented at VIVA
Study Outcomes Demonstrate Safety and Efficacy of Pantheris for Treatment of In-Stent RestenosisREDWOOD CITY, CA / ACCESSWIRE / October 7,...
Canadian Study Using Cloud DX Technology Proves Remote Patient Monitoring Improves Patient Outcomes
Research using Canadian technology by Cloud DX provides evidence healthcare decision-makers need; RPM improves patient outcomes and healthcare delivery.News in...
Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor
Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor Lugano,...
Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Tumor shrinkage and partial responses observed in patients with advanced head and neck squamous cell carcinoma (HNSCC) treated with MCLA-158In...
Sienna Maintains DBRS Ratings of “BBB” with Stable Trends
MARKHAM, Ontario, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) announced the...
Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment
Meeting, taking place October 7-10, 2021, is hosted by the American Association for Cancer Research (AACR), the National Cancer Institute...
Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
– Lead oral PRMT5 inhibitors PRT543 and PRT811 demonstrate favorable safety profile, evidence of preliminary clinical activity including durable responses...
Privia Health to Report Third Quarter 2021 Results on Monday, November 8
ARLINGTON, Va., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it plans to...
Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB), a commercial-stage biopharmaceutical...
Kinnate Biopharma Inc. Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference
First in human, multicenter, non-randomized, open-label trial has expanded to three sites and is actively recruitingSAN FRANCISCO and SAN DIEGO,...
Skye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development
SAN DIEGO, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary...
Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer
Data Demonstrate Novel Link Between GSPT1 and Myc-induced Transcription and Protein TranslationBOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Monte Rosa...
Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to...
Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering kt-2000 series PARP Inhibitors
VANCOUVER, British Columbia, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSX-V: RKV) today announced that the...